Advertisement
Screener

Allogene Therapeutics, Inc. (ALLO) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value

1.2 / 5 stars · 11/46 Roast Me

Allogene Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value

Allogene Therapeutics, Inc. (ALLO) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $93.15 million as of 2020-12-31, per its 10-K filed 2021-02-25.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2021-02-25

  • 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $93.15M.
  • 2019-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $110.49M.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
2020-12-31$93.15M
10-K · filed 2021-02-25
2019-12-31$110.49M
10-K · filed 2020-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Prime Medicine, Inc. (PRME)United States$0.557B-3.54
Aura Biosciences, Inc. (AURA)United States$0.639B-5.61
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Entera Bio Ltd. (ENTX)$0.485B
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10